Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Based on historical reporting patterns, DYN typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-05-11 | +$0.85 (+4.83%) | $1.14 (6.47%) | -$0.09 (-0.49%) | $0.79 (4.28%) |
| 2026-03-02 | +$0.53 (+3.39%) | $2.34 (14.98%) | -$1.55 (-9.60%) | $1.23 (7.62%) |
| 2025-11-05 | -$0.62 (-2.88%) | $1.06 (4.93%) | -$2.70 (-12.89%) | $3.95 (18.88%) |
| 2025-07-28 | -$0.64 (-6.43%) | $0.72 (7.24%) | -$0.11 (-1.18%) | $0.66 (7.09%) |
| 2025-05-08 | +$1.89 (+20.16%) | $2.52 (26.81%) | +$0.12 (+1.02%) | $0.83 (7.35%) |
| 2025-02-27 | -$0.62 (-4.50%) | $1.14 (8.27%) | +$0.44 (+3.34%) | $0.80 (6.07%) |
| 2024-11-12 | +$1.20 (+4.27%) | $3.39 (12.05%) | +$4.80 (+16.37%) | $6.66 (22.71%) |
| 2024-08-12 | -$0.53 (-1.22%) | $2.24 (5.14%) | +$0.57 (+1.32%) | $2.34 (5.43%) |
| Avg Abs Move | 5.96% | 10.73% | 5.78% | 9.93% |
Dyne Therapeutics has exhibited significant volatility around earnings events, with an average absolute Day 0 move of 5.96% and Day +1 move of 5.78%. The stock's intraday ranges are even more dramatic, averaging 10.73% on Day 0 and 9.93% on Day +1, indicating substantial two-way price action as investors digest results.
The directional pattern has been mixed but skewed slightly positive in recent quarters. The most dramatic move came in May 2025, when the stock surged 20.16% on Day 0 with an intraday range exceeding 26%. More recently, the May 2026 report produced a 4.83% Day 0 gain, while March 2026 saw a 3.39% initial pop followed by a -9.60% Day +1 decline, illustrating how follow-through can diverge from initial reactions.
Investors should prepare for substantial price movement, as seven of the last eight earnings events produced Day 0 or Day +1 moves exceeding 4%, with several instances of double-digit swings. The wide intraday ranges suggest active trading and position adjustments as market participants parse clinical updates and financial guidance.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 08/21/26 (DTE 28) |
| Expected Move | $1.42 (5.79%) |
| Expected Range | $23.09 to $25.93 |
| Implied Volatility | 90.59% |
The options market is pricing a 5.79% expected move for the August expiration, which sits slightly below DYN's average historical Day 0 move of 5.96% and Day +1 move of 5.78%. This suggests options traders are anticipating a typical earnings reaction rather than an outsized event, though the 90.59% implied volatility reflects the elevated uncertainty inherent in clinical-stage biotech earnings.
Part 3: What Analysts Are Saying
Analyst sentiment on Dyne Therapeutics is overwhelmingly bullish, with the consensus rating at 4.63 out of 5.0, firmly in Strong Buy territory. The breakdown shows 15 Strong Buys, 1 Moderate Buy, and 3 Holds, with no sell ratings among the 19 analysts covering the stock. This represents improved sentiment from a month ago, when there were 13 Strong Buys, as two additional analysts upgraded their stance.
The average price target of $38.38 implies 57% upside from the current price of $24.44, reflecting substantial conviction in the company's long-term value proposition. The range of targets is wide, spanning from a low of $17.00 to a high of $50.00, indicating divergent views on the probability and timeline for clinical and commercial success. The high-end target suggests some analysts see potential for the stock to more than double if key milestones are achieved.
The recent strengthening of analyst sentiment, with the consensus improving from 4.59 to 4.63 over the past month and two net upgrades to Strong Buy, signals growing confidence in DYN's execution and pipeline prospects heading into this earnings report.
Part 4: Technical Picture
Dyne Therapeutics enters earnings with exceptionally strong technical momentum. The Barchart Technical Opinion stands at 100% Buy, maintaining that maximum bullish reading consistently over the past week and month. This unwavering strength reflects sustained buying pressure and positive price action leading into the report.
Timeframe Analysis:
- Short-term (100% Buy): Maximum buy signal indicates powerful near-term momentum with no technical deterioration
- Medium-term (100% Buy): Sustained strength across the intermediate timeframe confirms this is not just a short-term spike but a broader uptrend
- Long-term (100% Buy): Full buy signal in the longer-term view suggests the stock has established a durable upward trajectory
Trend Characteristics: The signal strength is characterized as Strong with direction in the Top 1%, indicating DYN is exhibiting some of the most powerful technical momentum in the entire market heading into earnings.
The stock is trading above all key moving averages, with the current price of $24.44 above the 5-day ($23.76), 10-day ($23.67), 20-day ($23.21), 50-day ($20.26), 100-day ($19.22), and 200-day ($18.83) moving averages.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $23.76 | 50-Day MA | $20.26 |
| 10-Day MA | $23.67 | 100-Day MA | $19.22 |
| 20-Day MA | $23.21 | 200-Day MA | $18.83 |
The progressive stacking of moving averages in bullish alignment—with each shorter-term average above longer-term averages—confirms a healthy uptrend structure. The stock has gained 29.8% from its 200-day moving average, indicating substantial momentum but also raising the stakes for this earnings report. The technical setup is highly supportive heading into the release, but the extended nature of the rally means any disappointment could trigger profit-taking. Conversely, positive results could propel the stock toward the analyst price target range, as there are no overhead technical resistance levels to constrain upside.